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We read with interest the article 'JACIE accreditation for blood and
marrow transplantation: past, present and future directions of an
international model for healthcare quality improvement' published
in the March 2017 issue of Bone Marrow Transplantation. This
manuscript makes future inferences through presenting an
assessment about quality standards for blood and bone marrow
transplantation, and also discusses the benefits of international
quality standards on clinical and laboratory practice, and potential
disadvantages.1
The leaders of the European Society for Blood and Marrow
Transplantation (EBMT) and transplant centres expect that accred-
itation by the Joint Accreditation Committee: International Society
for Cellular Therapy and EBMT (or JACIE for short) will improve
communication between transplant centres, provide a uniform
approach for donor safety and, most importantly, enable the
transplant teams to improve.1–3 Several studies have reported the
influence of JACIE accreditation on the prolongation of lifespan and
reduction of transplant-related mortality.2,3 However, it is not clear
how the JACIE-accredited centres feel about this and which
objective benefits are important. While efforts for JACIE
accreditation are overwhelmingly in high-income economies in
Europe, transplant activity is gradually increasing outside these
countries.4 It is important to recognize that quality improvement
and accreditation is not inhibitory to the blood and marrow
transplantation activities in developing economies so that the
professionals in this field are willing for accreditation. Supporting
this opinion, we aimed to present the objective benefits our
re-accredited centre (T 644) showing the perspective of an
accredited centre. We suggest that such data are an important
motivator for centres to become accredited.
Our centre has been accredited for 5 years (EBMT CIC 589) as
one of two re-accredited centres in our country and has achieved
the following. The transplant team has been intact for 10 years.
We believe that the accreditation efforts have helped to motivate
people to work towards the same goal. The number of patients
referred to our centre and transplant activity has increased from
40 to 96 patients per year. None of the 448 patients who
underwent stem cell transplant (SCT) during the accreditation
period complained or sued our institution, and also satisfactory
outcomes could be achieved. This is important for the transplant
team, who use complex, challenging treatment methods.
Transplant-related mortality was found to be significantly reduced
after accreditation (5.5% vs 1.5% for auto-SCT and 18.4% vs 8.1%
for allo-SCT). Our transplant centre was the first running among
the 47 adult SCT centres countrywide with regard to post
transplant-100-day mortality for both transplant types according
to the 2014–2015 assessment of the Ministry of Health. A clinical
data management system, the PRANA project, was developed to
help ensure that our work was in accordance with international
standards. The project included a transplant coordinator software
that facilitates traceability and work flow and uses current
classifications and side-effects terminology. Other improvements
include an ISBT 128-compatible cellular-therapy-monitoring
system using TURUNÇ software and an on-line SOP education
system providing information for patients/donors using
INFORMARATE software.5,6 Our centre provided the greatest
support of any centre in Turkey, for stem cell collection for
TURKOK, the National Stem Cell Donor Bank and the transplant
centres abroad.
Collaboration is known to be essential for the success of team
work. Therefore, the members of the transplant team were given
two structured questionnaires enquiring about their perspectives
on the re-accreditation process. According to the questionnaires
which were completed by 84 (97.6%) subjects, 96% believe that re-
accreditation is necessary and were willing to work to achieve it.
Currently, a national JACIE collaboration project supported by the
National Haematology Society is being conducted with the aim of
generalising JACIE studies (http://www.thd.org.tr/thdData/userfiles/
file/jacie-ulusal-isbirligi-projesi.pdf).
Overall, the accreditation motivated team members and
facilitated their work, leading to substantial improvements. The
development studies are reflected in the transplant team
dynamics, as evaluated by both the accreditation committee
and from the perspective of an accredited centre. We believe that
the National JACIE representatives should take responsibility for
standardising accreditation studies countrywide.
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